Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 684-689

  Jung, Seung Min ^a   Jang, Jeong Won ^a   You, Chan Ran ^a   Yoo, Sun Hong ^a   Kwon, Jung Hyun ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a   Chung, Kyu Won ^a   Kay, Chul Seung ^a   Jung, Hyun Suk ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Extrahepatic metastasis; Hepatocellular carcinoma; Intrahepatic tumor control; Radiation therapy; Survival

Indexed keywords

ADULT; ARTICLE; CANCER CONTROL; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CAUSE OF DEATH; CHEMOEMBOLIZATION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TOMOTHERAPY; TREATMENT OUTCOME;

EID: 84863341402     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06917.x     Document Type: Article

References (40)

1. World Health Organization. Global Health Observatory Data Repository. Cited 16 Oct 2011. Available from URL:
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 2003; 139: 817-23.
3. Statistics Korea. National Cancer Information Center. Cited 16 Oct 2011. Available from URL:
4. Taura N, Hamasaki K, Nakao K etal. The impact of newer treatment modalities on survival in patients with hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2006; 4: 1177-83.
5. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 2009; 27: 1485-91.
6. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.
7. Chan KM, Yu MC, Wu TJ etal. Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J. Gastroenterol. 2009; 15: 5481-8.
8. Lin CC, Liang HP, Lee HS etal. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J. Gastroenterol. Hepatol. 2009; 24: 815-20.
9. Koide N, Kondo H, Suzuki K, Asamura H, Shimada K, Tsuchiya R. Surgical treatment of pulmonary metastasis from hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 152-6.
10. Yoon YS, Kim HK, Kim J etal. Long-term survival and prognostic factors after pulmonary metastasectomy in hepatocellular carcinoma. Ann. Surg. Oncol. 2010; 17: 2795-801.
11. Jang JW, Kay CS, You CR etal. Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 412-18.
12. Park YJ, Lim do H, Paik SW etal. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J. Gastroenterol. 2006; 41: 1099-106.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
14. Jang JW, Park YM, Bae SH etal. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2004; 54: 415-20.
15. Jang JW, Bae SH, Choi JY etal. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother. Pharmacol. 2007; 59: 9-15.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010; 30: 52-60.
17. Kanda M, Tateishi R, Yoshida H etal. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008; 28: 1256-63.
18. Natsuizaka M, Omura T, Akaike T etal. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol. 2005; 20: 1781-7.
19. Tanaka K, Shimada H, Matsuo K, Takeda K, Nagano Y, Togo S. Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection. World J. Surg. 2008; 32: 1738-47.
20. Okusaka T, Okada S, Ishii H etal. Prognosis of hepatocellular carcinoma patients with extrahepatic metastases. Hepatogastroenterology 1997; 44: 251-7.
21. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
22. Poon D, Anderson BO, Chen LT etal. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10: 1111-18.
23. Finn RS. Drug therapy: sorafenib. Hepatology 2010; 51: 1843-9.
24. Worns MA, Weinmann A, Pfingst K etal. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 489-95.
25. Mayor S. NICE rules that drug used in advanced liver cancer is not cost effective for the NHS. BMJ 2009; 339: b4956.
26. Uka K, Aikata H, Takaki S etal. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J. Gastroenterol. 2007; 13: 414-20.
27. Zhang SM, Zeng ZC, Tang ZY etal. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol. Int. 2008; 2: 237-43.
28. Kim SU, Kim do Y, Park JY etal. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J. Cancer Res. Clin. Oncol. 2008; 134: 1377-84.
29. Choi HJ, Cho BC, Sohn JH etal. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J. Neurooncol. 2009; 91: 307-13.
30. Chang L, Chen YL, Kao MC. Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. Surg. Neurol. 2004; 62: 172-7.
31. Lee JO, Lee KW, Oh DY etal. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann. Oncol. 2009; 20: 1402-7.
32. Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J. Gastroenterol. 2009; 15: 713-16.
33. Asnacios A, Fartoux L, Romano O etal. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008; 112: 2733-9.
34. Sawada Y, Iwamoto S, Yurino N etal. Rupture of hepatocellular carcinoma with multiple pulmonary metastasis successfully treated by transcatheter arterial embolization (TAE) of tumor: a case report. Gan To Kagaku Ryoho Cancer & Chemother. 1991; 18: 2471-5.
35. Heianna J, Miyauchi T, Suzuki T, Ishida H, Hashimoto M, Watarai J. Spontaneous regression of multiple lung metastases following regression of hepatocellular carcinoma after transcatheter arterial embolization. A case report. Hepatogastroenterology 2007; 54: 1560-2.
36. Ohba K, Omagari K, Nakamura T etal. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998; 43: 575-7.
37. O'Beirne JP, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2004; 16: 1257-60.
38. Cole WH. Efforts to explain spontaneous regression of cancer. J. Surg. Oncol. 1981; 17: 201-9.
39. Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat. Rev. 2005; 31: 159-72.
40. Abiru S, Kato Y, Hamasaki K, Nakao K, Nakata K, Eguchi K. Spontaneous regression of hepatocellular carcinoma associated with elevated levels of interleukin 18. Am. J. Gastroenterol. 2002; 97: 774-5.